Replimune Group, Inc.
REPLDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
How REPL's past catalysts played out
Vusolimogene Oderparepvec
Advanced Melanoma
RP2
Metastatic Uveal Melanoma
RP3
Refractory Metastatic Colorectal Cancer
RP2 Monotherapy
Hepatocellular Carcinoma
RP1
Non-Small Cell Lung Cancer (NSCLC)
RP1, intra-tumoral injection, oncolytic virus
Cutaneous Squamous Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vusolimogene Oderparepvec | Phase 3 | Advanced Melanoma | - | - |
RP2 | Phase 3 | Metastatic Uveal Melanoma | - | - |
RP3 | Phase 2 | Refractory Metastatic Colorectal Cancer | - | - |
RP2 Monotherapy | Phase 2 | Hepatocellular Carcinoma | - | - |
RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
RP1, intra-tumoral injection, oncolytic virus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
cutaneous melanoma
1 drug in this indication
melanoma
1 drug in this indication
Advanced melanoma
1 drug in this indication
Unresectable Advanced Cutaneous Melanoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Replimune Group, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Replimune Group, Inc.'s (REPL) pipeline across Phase 3, Phase 2. Its lead program is Vusolimogene Oderparepvec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Replimune Group, Inc.'s next FDA catalyst?→
Replimune Group, Inc.'s (REPL) next tracked catalyst is a Phase 2 expected January 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REPL biotech catalysts?→
Add REPL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Replimune Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.